参考来源:
[1]Mullard A.Immuno-oncology target TIGIT attracts a new contender.Nat Rev Drug Discov.2021 Aug;20(8):576.doi:10.1038/d41573-021-00123-6.PMID:34239092.
[2]Chauvin JM,et al.IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma.Clin Cancer Res.2020 Oct 15;26(20):5520-5533.doi:10.1158/1078-0432.CCR-20-0575.Epub 2020 Jun 26.PMID:32591463;PMCID:PMC8045409.
[3]https://www.genentechoncology.com/pipeline-molecules/tiragolumab.html
[4]Jeong BS,et al.Structural and functional characterization of a monoclonal antibody blocking TIGIT.MAbs.2022 Jan-Dec;14(1):2013750.doi:10.1080/19420862.2021.2013750.PMID:35090381;PMCID:PMC8803117.
[5]https://ascopost.com/issues/august-10-2020/anti-tigit-antibody-plus-atezolizumab-move-forward-in-advanced-nsclc/
[6]DEREK LOWE:Hold the Synergy For Now.1/24/2022
https://www.science.org/content/blog-post/hold-synergy-now
[7]DEREK LOWE:TIGIT Troubles.5/12/2022
https://www.science.org/content/blog-post/tigit-troubles
[8]https://www.gene.com/media/press-releases/14937/2021-12-10/new-data-from-the-phase-ii-cityscape-tri
[9]Herbst RS,et al.Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC.N Engl J Med.2020 Oct 1;383(14):1328-1339.doi:10.1056/NEJMoa1917346.PMID:32997907.
[10]Tawbi HA,et al.Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.N Engl J Med.2022 Jan 6;386(1):24-34.doi:10.1056/NEJMoa2109970.PMID:34986285.
[11]He M,Chai Y,Qi J,Zhang CWH,Tong Z,Shi Y,Yan J,Tan S,Gao GF.Remarkably similar CTLA-4 binding properties of therapeutic ipilimumab and tremelimumab antibodies.Oncotarget.2017 May 19;8(40):67129-67139.doi:10.18632/oncotarget.18004.PMID:28978021;PMCID:PMC5620161.
[12]Jacob Plieth:At long last,tremelimumab scores.5/7/2021
https://www.evaluate.com/vantage/articles/news/snippets/long-last-tremelimumab-scores
[13]Jason Mast:After 18 years in development,AstraZeneca’s CTLA-4 antibody gets the red carpet treatment at the FDA.4/25/2022
https://endpts.com/after-18-years-in-development-astrazenecas-ctla-4-antibody-gets-the-red-carpet-treatment-at-the-fda/